Replies to post #101054 on Biotech Values

[DewDiligence]

Re: Ex-US market for generic Copaxone

What steps would MNTA have to take to market Copaxone in India and Ukraine like Natco/MYL?

I don’t expect NVS and MNTA to have any interest in developing a Copaxone product in markets such as India and Ukraine. That Natco is already doing it makes it even less attractive from a business standpoint.

MNTA’s interest in generic Copaxone will likely be limited to the US, which accounts for about 70% of worldwide Copaxone sales. Most of the remaining 30% comes from the EU, but only a few EU countries allow US-style automatic substitution of a generic for a branded drug. In short, the business proposition for developing generic Copaxone in non-US markets is tenuous at best.